BioRestorative Therapies Q2 2023 Earnings Report $1.80 -0.16 (-8.16%) As of 02/21/2025 04:00 PM Eastern Earnings History BioRestorative Therapies EPS ResultsActual EPS-$0.77Consensus EPS -$1.56Beat/MissBeat by +$0.79One Year Ago EPSN/ABioRestorative Therapies Revenue ResultsActual Revenue$0.07 millionExpected Revenue$0.03 millionBeat/MissBeat by +$40.00 thousandYoY Revenue GrowthN/ABioRestorative Therapies Announcement DetailsQuarterQ2 2023Date8/11/2023TimeN/AConference Call ResourcesBRTX Earnings History BioRestorative Therapies Earnings HeadlinesBioRestorative Therapies- BRTX-100 program receives FDA Fast Track designationFebruary 20 at 12:26 PM | markets.businessinsider.comBRTX-100 Front and Center at ORS 2025February 10, 2025 | markets.businessinsider.comWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nice stream of income along the way.February 23, 2025 | Behind the Markets (Ad)BioRestorative Therapies announces new data on BRTX-100 presented at ORS 2025February 10, 2025 | markets.businessinsider.comPleasing Signs As A Number Of Insiders Buy BioRestorative Therapies StockDecember 26, 2024 | uk.finance.yahoo.comRoth MKM Remains a Buy on BioRestorative Therapies (BRTX)November 16, 2024 | markets.businessinsider.comSee More BioRestorative Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioRestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioRestorative Therapies and other key companies, straight to your email. Email Address About BioRestorative TherapiesBioRestorative Therapies (OTCMKTS:BRTX) engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.View BioRestorative Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)ONEOK (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Home Depot (2/25/2025)Public Storage (2/25/2025)Sempra (2/25/2025)NVIDIA (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
